Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus AI (NASDAQ:TEM) launched the next-generation of Lens, an agentic AI platform for oncology drug development and research. The platform connects Tempus multimodal data, AI tooling and computing to generate evidence faster.
Lens uses over a decade of longitudinal real-world data, more than 8.5 million de-identified patient records, oncology foundation models, and validated AI agents, and is already used by 19 of the top 20 largest biopharma companies.
Tempus (NASDAQ:TEM) launched the national PRECISION Challenge to accelerate oncology breakthroughs using its multimodal foundation model. The program offers selected research teams structured access to Tempus’ de-identified clinical, molecular, and imaging data, AI models, and compute via Lens Workspaces, plus staged grants of $25,000 and $75,000.
Tempus AI (NASDAQ:TEM) launched Tempus Preview, an AI-powered application that provides preliminary genomic insights within about 24 hours of tissue receipt. It is designed to bridge the time gap between ordering a diagnostic test and receiving final sequencing results in precision oncology.
At launch, Tempus Preview targets high-impact biomarkers, including MSI-H in several solid tumors, EGFR mutations in NSCLC, and rare FGFR fusions in hepatobiliary and bladder cancers, using the Paige Predict AI model validated for clinical use.
Tempus AI (NASDAQ:TEM) reported initial results from its multimodal foundation models for oncology insight generation, built on more than 500 petabytes of de-identified clinical, genomic, imaging, and transcriptomic data.
The latest transformer-based patient trajectory model, trained on 2.5 million longitudinal records, showed prognostic value in NSCLC and potential utility for clinical trial design and drug development.
Tempus (NASDAQ:TEM) received FDA approval for a tumor-only indication for its xT CDx next-generation sequencing platform, a 648-gene tissue-based assay for comprehensive genomic profiling of solid tumors.
The approval enables migration of Tempus’ entire DNA solid tumor portfolio to FDA-approved assays under unified ADLT pricing, with an estimated $200 ASP benefit from 2027, according to the company.
Tempus AI (NASDAQ:TEM) announced a major expansion of its AI-enabled Next platform to deliver real-time clinical intelligence and close care gaps in oncology.
The platform now supports six new clinical scenarios and is backed by a multi-center eNSCLC study showing higher biomarker testing and guideline-concordant therapy.
Tempus AI (NASDAQ: TEM) announced a major upgrade to its smart physician platform Tempus Hub on May 27, 2026. The platform now embeds a next-generation, agentic generative AI co-pilot directly into Hub to support oncology clinical workflows at the point of care.
Key features include proactive AI genomic patient insights, instant generation of patient-specific documentation using Tempus data, and future plans to connect genomics results with Tempus’ longitudinal patient registry and HIE data. The upgrade builds on Tempus’ Edge, Locker, and Air infrastructure to link AI with real-time healthcare data.
Tempus AI (NASDAQ:TEM) announced that 37 abstracts have been accepted for presentation at the 2026 ASCO Annual Meeting, held May 29–June 3 in Chicago.
Accepted research spans AI-augmented histopathology, RNA-based algorithms, real-world treatment outcomes, AI-enabled biomarker testing tools, whole genome sequencing, and minimal residual disease monitoring across multiple solid and hematologic cancers.
Tempus AI (NASDAQ:TEM) announced the clinical launch of the ArteraAI Prostate Test (mHSPC), a CLIA-certified, CAP-accredited prognostic digital pathology test for metastatic hormone-sensitive prostate cancer. Fully integrated into the Tempus platform, it combines biopsy image analysis with clinical data and Tempus’ NGS results to personalize therapy intensity.
The test is the first externally developed digital pathology algorithm available for clinical use within the Tempus ecosystem and targets an estimated 25,000 newly diagnosed metastatic prostate cancer patients annually in the U.S. Clinicians can order it as an add-on across Tempus’ solid tumor portfolio.
Bristol Myers Squibb (NYSE: BMY) and Tempus AI announced an expanded collaboration using AI, multimodal real-world data, and the Tempus Lens platform to optimize clinical trial design and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial development programs.
The initiative supports solid tumor oncology assets in lung, colon, and prostate cancers and extends into neuroscience for Alzheimer’s disease. It focuses on refining trial assumptions, characterizing complex patient populations, validating control groups, and identifying optimal patient segments for investigational therapies.